Bristol-Myers Gets Europe OK for Sprycel in Form of Leukemia

Datum : 11/02/2019 @ 13h47
Quelle : Dow Jones News
Name : Bristol-Myers Squibb Company (BMY)
Kurs : 51.67  0.84 (1.65%) @ 00h55
Bristol Myers Sqibb share price Chart

Bristol-Myers Gets Europe OK for Sprycel in Form of Leukemia

Bristol Myers Sqibb (NYSE:BMY)
Historical Stock Chart

1 Monat : Von Jan 2019 bis Feb 2019

Click Here for more Bristol Myers Sqibb Charts.
   By Colin Kellaher 
 

Bristol-Myers Squibb Co. (BMY) on Monday said the European Commission approved the company's Sprycel in combination with chemotherapy for children with a form of leukemia.

The New York biopharmaceutical company said the approval covers the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia and includes both the tablet and powder formulations.

Bristol-Myers said the approval marks the second pediatric leukemia indication for Sprycel in Europe.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

February 11, 2019 07:32 ET (12:32 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Kürzlich von Ihnen besucht
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

Der Markt LS (Lang&Schwarz) wird als Realtime Indikation kostenlos angezeigt und bietet Ihnen außerbörsliche Realtime Aktienkurse in der Zeit von Mo-Fr 08:00 bis 23:00, Samstags 10:00 bis 13:00 und Sonntags an.
NYSE und AMEX Kurse sind um mindestens 20 Minuten zeitverzögert.
Alle weiteren Kurse sind um mindestens 15 Minuten zeitverzögert, sofern nicht anders angegeben.
P: V:de D:20190216 15:19:41